---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-046588"
form_type: "8-K"
ticker: "OM"
cik: "0001484612"
company_name: "Outset Medical, Inc."
filed_at: "2026-02-11T23:59:59+00:00"
generated_at: "2026-05-16T03:16:53.600309+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Outset Medical reports FY2025 revenue $119.5M (+5% YoY); provides 2026 guidance $125-130M

## Summary
- Q4 revenue $28.9M; full year 2025 revenue $119.5M (+5% YoY); recurring revenue $88.7M (+6%).
- Gross margin expanded to 42.4% in Q4 (non-GAAP 42.9%), up ~600 bps vs Q4 2024.
- Net loss narrowed to $81.7M in 2025 from $128M in 2024; cash $173M; ops cash burn $46M vs $116M.
- Received FDA clearance for next-generation Tablo platform; launch expected in Q2 2026.
- FY2026 guidance: revenue $125M-$130M (+5-9% YoY); non-GAAP gross margin low to mid-40%.

## SEC filing metadata
- accession: 0001193125-26-046588
- form_type: 8-K
- ticker: OM
- cik: 0001484612
- company_name: Outset Medical, Inc.
- filed_at: 2026-02-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1484612/000119312526046588/0001193125-26-046588-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1484612/000119312526046588/om-20260211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-046588
- JSON: https://secwatch.observer/filing/0001193125-26-046588.json
- Plain text: https://secwatch.observer/filing/0001193125-26-046588.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.